INTEZYNE TECHNOLOGIES, INC. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all

INTEZYNE TECHNOLOGIES, INC. — SBIR Phase I award from Department of Health and Human Services.

Amount
$156,868
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase I
Solicitation
PAR10-286
NAICS
Place of performance
FL
Period

Description

DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In certain cases, such as bone cancer, chemotherapy has very limited effectiveness. In order to address these shortcomings, drug delivery innovations are necessary toimprove the success rate of these treatments and improve the quality of life for these patients. Drug delivery vehicles are needed that are stable t post-administration dilution, can avoid biological barriers (e.g. reticuloendothelial system (RES) uptake), and deliver drugs in response to a physiological stimuli encountered in solid tumor environment (i.e. change in the pH level). Polymer micelles formed by the assembly of amphiphilic block copolymers are a particular type of nanocarrier that are attr